(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large…
Source link : https://www.medpagetoday.com/cardiology/prevention/119074
Author :
Publish date : 2025-12-17 22:47:00
Copyright for syndicated content belongs to the linked Source.
